Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma

Journal of Clinical Investigation

Volumn 126, Issue 9, 2016, Pages 3351-3362

  Cardenas, Mariano G ^a   Yu, Wenbo ^b   Beguelin, Wendy ^a   Teater, Matthew R ^a   Geng, Huimin ^a,c   Goldstein, Rebecca L ^a   Oswald, Erin ^a   Hatzi, Katerina ^a   Yang, Shao Ning ^a   Cohen, Joanna ^a   Shaknovich, Rita ^a   Vanommeslaeghe, Kenno ^b,d   Cheng, Huimin ^b   Liang, Dongdong ^b   Cho, Hyo Je ^e   Abbott, Joshua ^e   Tam, Wayne ^a   Du, Wei ^a   Leonard, John P ^a   Elemento, Olivier ^a   Cerchietti, Leandro ^a   Cierpicki, Tomasz ^e   Xue, Fengtian ^b   MacKerell, Alexander D ^b   Melnick, Ari M ^a   more..

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD69 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DOXORUBICIN; FX1; PROTEIN BCL 6; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; BCL6 PROTEIN, HUMAN; FX1 THIAZOLIDINEDIONE COMPOUND; INDOLE DERIVATIVE; LIGAND; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; HEK293 CELL LINE; HETERONUCLEAR SINGLE QUANTUM COHERENCE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; LARGE CELL LYMPHOMA; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; DRUG DESIGN; DRUG SCREENING; GENE EXPRESSION REGULATION; GENE TRANSLOCATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; METABOLISM; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOXORUBICIN; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; INDOLES; LIGANDS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-BCL-6; THIAZOLIDINEDIONES; TRANSLOCATION, GENETIC;

EID: 84987788606     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI85795     Document Type: Article

References (39)

1. Evans LS, Hancock BW. Non-Hodgkin lymphoma. Lancet. 2003;362(9378):139-146
2. Hatzi K, Melnick A. Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis. Trends Mol Med. 2014;20(6):343-352
3. Klein U, Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol. 2008;8(1):22-33
4. Alizadeh AA, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503-511
5. Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med. 2010;362(15):1417-1429
6. Coiffier B, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242
7. Habermann TM, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(19):3121-3127
8. Pfreundschuh M, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12(11):1013-1022
9. Sehn LH, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23(22):5027-5033
10. Iqbal J, et al. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia. 2007;21(11):2332-2343
11. Bea S, et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve geneexpression-based survival prediction. Blood. 2005;106(9):3183-3190
12. Green MR, et al. Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma. Nat Commun. 2014;5:3904
13. Ye BH, et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet. 1997;16(2):161-170
14. Dent AL, Shaffer AL, Yu X, Allman D, Staudt LM. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science. 1997;276(5312):589-592
15. Fukuda T, et al. Disruption of the Bcl6 gene results in an impaired germinal center formation. J Exp Med. 1997;186(3):439-448
16. Baron BW, et al. The human BCL6 transgene promotes the development of lymphomas in the mouse. Proc Natl Acad Sci U S A. 2004;101(39):14198-14203
17. Cattoretti G, et al. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell. 2005;7(5):445-455
18. Huynh KD, Bardwell VJ. The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT. Oncogene. 1998;17(19):2473-2484
19. Huynh KD, Fischle W, Verdin E, Bardwell VJ. BCoR, a novel corepressor involved in BCL-6 repression. Genes Dev. 2000;14(14):1810-1823
20. Ahmad KF, et al. Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain. Mol Cell. 2003;12(6):1551-1564
21. Ghetu AF, Corcoran CM, Cerchietti L, Bardwell VJ, Melnick A, Privé GG. Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer. Mol Cell. 2008;29(3):384-391
22. Huang C, Hatzi K, Melnick A. Lineage-specific functions of Bcl-6 in immunity and inflammation are mediated by distinct biochemical mechanisms. Nat Immunol. 2013;14(4):380-388
23. Polo JM, et al. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med. 2004;10(12):1329-1335
24. Cerchietti LC, et al. A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood. 2009;113(15):3397-3405
25. Cerchietti LC, et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell. 2010;17(4):400-411
26. Guvench O, MacKerell AD. Computational fragment-based binding site identification by ligand competitive saturation. PLoS Comput Biol. 2009;5(7):e1000435
27. Raman EP, Yu W, Lakkaraju SK, MacKerell AD. Inclusion of multiple fragment types in the site identification by ligand competitive saturation (SILCS) approach. J Chem Inf Model. 2013;53(12):3384-3398
28. Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem. 2010;53(7):2719-2740
29. Seidel SA, et al. Microscale thermophoresis quantifies biomolecular interactions under previously challenging conditions. Methods. 2013;59(3):301-315
30. Wienken CJ, Baaske P, Rothbauer U, Braun D, Duhr S. Protein-binding assays in biological liquids using microscale thermophoresis. Nat Commun. 2010;1:100
31. Zuiderweg ER. Mapping protein-protein interactions in solution by NMR spectroscopy. Biochemistry. 2002;41(1):1-7
32. Hatzi K, et al. A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters. Cell Rep. 2013;4(3):578-588
33. Shaffer AL, Yu X, He Y, Boldrick J, Chan EP, Staudt LM. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity. 2000;13(2):199-212
34. Polo JM, et al. Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proc Natl Acad Sci U S A. 2007;104(9):3207-3212
35. Hans CP, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-282
36. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2003;100(17):9991-9996
37. Cerchietti L, Melnick A. Targeting BCL6 in diffuse large B-cell lymphoma: what does this mean for the future treatment?. Expert Rev Hematol. 2013;6(4):343-345
38. Wells JA, McClendon CL. Reaching for highhanging fruit in drug discovery at protein-protein interfaces. Nature. 2007;450(7172):1001-1009
39. Evans SE, et al. The ansamycin antibiotic, rifamycin SV, inhibits BCL6 transcriptional repression and forms a complex with the BCL6-BTB/POZ domain. PLoS One. 2014;9(3):e90889